Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients

Mina Hayashi, Tsuyoshi Kouki, Nobuyuki Takasu, Sumito Sunagawa and Ichiro Komiya
Department of Endocrinology and Metabolism, Internal Medicine, University of the Ryukyus, Uehara 207, Nishihara, Okinawa 903-0215, Japan
(Correspondence should be addressed to T Kouki; Email: tkouki@ryuder2nai.com)

Abstract

Objective: Programmed cell death-1 (PD-1) and its ligands (PD-L1 and PD-L2) inhibit T-cell proliferation and activation. This inhibition down-regulates the immune responses. The association of a PD-L1 polymorphism with Graves' disease (GD) was studied.

Design: The association of an A/C polymorphism at position 8923 in PD-L1 intron 4 with GD was studied.

Patients: The study included 327 GD patients and 192 controls, of which 252 GD patients were followed over 5–10 years.

Measurements: PD-L1 intron 4 position 8923 A/C polymorphism was typed using the PCR-restriction fragment length polymorphism method.

Results: The A/C genotype frequencies were significantly different between GD patients and controls. The A/C and C/C frequencies were higher in GD patients than in controls. The A/A frequencies were lower in GD patients than in controls. A total of 252 GD patients were followed over 5–10 years; 200 had discontinued antithyroid drugs (ATD) while 52 continued to take ATD. Of these 200, 176 continued to be in remission and 24 had relapsed into hyperthyroidism. Significant differences in the duration of positive TBII, positive thyroid-stimulating antibodies, and ATD treatment were noted between the patients in remission and those that had relapsed. Significant differences in the A- and C-allele frequencies were noted between the two. The C-allele frequency was higher in GD patients who did not achieve remission than in those who achieved remission.

Conclusion: An A/C polymorphism at position 8923 in PD-L1 is associated with GD. The PD-L1 polymorphism plays a role in GD development. GD patients with the C allele at position 8923 in PD-L1 gene had difficulty in achieving remission.
and GD. This is the first report to demonstrate an association between a PD-L1 gene polymorphism and GD. An A/C polymorphism at position 8923 in PD-L1 gene affects the GD development.

Methods

Subjects

Whole blood specimens with EDTA were obtained from the subjects. The subjects were recruited between 1 January 1993 and 31 December 2001. They were all Japanese. A total of 327 patients with GDs were studied (262 women and 65 men, aged 15–75 years). An A/C polymorphism at position 8923 in PD-L1 gene was analyzed in these 327 Graves’ patients. A total of 252 Graves’ patients were followed over 5–10 years. The other 75 Graves’ patients were not followed. In addition, the 192 normal control subjects were also observed (154 women and 38 men, aged 19–75 years). These 192 normal control subjects did not have a goiter. They also denied any personal or family histories of autoimmune thyroid diseases. They were negative for thyrotrophin (TSH) receptor antibodies (TRAb), thyroglobulin antibodies (TGAb), and thyroid peroxidase antibodies (TPOAb). GD was diagnosed on the basis of histories and the laboratory findings, including elevated serum thyroxine (T4) and tri-iodothyronine (T3) concentrations, undetectable serum TSH levels, and positive TRAb (18, 19). TRAb was measured as TSH-binding inhibitory immunoglobulin (TBII) (20) and thyroid-stimulating antibodies (TSAb) (18). TBII was measured using a commercially available kit (RSR Ltd, Cardiff, UK). A receiver operating characteristic curve analysis (21) was conducted to evaluate the TBII and TSAb values for the GD diagnosis (20). The cutoff value for TBII was 10% (sensitivity 95.67% with 95% confidence limits (93.27–98.07%) and specificity 98.62% with 95% confidence limits (97.87–99.37%)) (18).

Table 1 shows the clinical findings of the 252 Graves’ patients who had been followed for 5–10 years. After the diagnosis of GD was made, the patients were treated with methimazole (or propylthiouracil; antithyroid drugs (ATD)) at initial doses of 20–30 (or 200–300) mg/day. These doses were gradually reduced. They received the minimum doses of ATD necessary to maintain the normal levels of serum T4, T3, and TSH. The patients were seen every 2–4 weeks until their serum T4 and T3 concentrations had become normal. They were then followed every 4 weeks. TBII and TSAb were measured every 1–3 months. Of the 252 patients, 200 of them (group 1), who had had negative TBII and negative TSAb and normal serum levels of T3, T4, and TSH over the previous 1 year, had discontinued ATD, while 52 patients (group 2), who continued to have positive TBII and/or positive TSAb, continued to take ATD. The 200 patients (group 1), who had had negative TBII and negative TSAb and normal serum levels of T3, T4, and TSH over the previous 1 year, had all discontinued ATD. These patients were seen every 1–3 months. If the patients continued to be in a euthyroid state and to have negative TSAb and negative TBII at 1 year after ATD discontinuation, they were considered to be in remission (19). Of these 200 Graves’ patients in group 1, 176 patients were in remission (group 1A) while the other 24 patients relapsed into hyperthyroidism (group 1B). No significant differences in the gender ratio, the ages at diagnosis, and the titers of TBII and TSAb before treatment were noted between groups 1 and 2, or between groups 1A and 1B. Significant differences in the durations of positive TBII, positive TSAb, and ATD treatment were noted between groups 1A and 1B. Early disappearances of TBII and TSAb predict the remission (22). We studied the frequencies of AA, AC,

Table 1 Clinical findings of the 252 Graves’ patients.

<table>
<thead>
<tr>
<th>Group (number of cases)</th>
<th>Women/men</th>
<th>Agesa</th>
<th>Before ATD treatment</th>
<th>Durations (years)</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1 (200)b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group 1A (176)c</td>
<td>145/31</td>
<td>38.5±16.5</td>
<td>49.8±24.3</td>
<td>592±196</td>
<td>2.8±1.8</td>
<td>3.0±1.8</td>
<td>4.0±2.4</td>
</tr>
<tr>
<td>Group 1B (24)d</td>
<td>19/5</td>
<td>38.8±17.5</td>
<td>50.1±21.5</td>
<td>673±215</td>
<td>5.3±2.4</td>
<td>5.8±2.9</td>
<td>6.9±2.9</td>
</tr>
<tr>
<td>Group 2 (52)e</td>
<td>42/10</td>
<td>38.0±19.5</td>
<td>56.2±28.6</td>
<td>779±395</td>
<td>Having positive TBII and/or TSAb</td>
<td>Taking ATD</td>
<td></td>
</tr>
</tbody>
</table>

Values are the means ± s.d. ATD, antithyroid drugs; TBII, TSH-binding inhibitory immunoglobulin; TSAb, thyroid stimulating antibody. No significant differences in the ages at diagnosis and the titers of TBII and TSAb before treatment were noted between groups 1 and 2, or between groups 1A and 1B. Significant differences were noted between groups 1A and 1B regarding the durations of positive TBII (P=0.020), positive TSAb (P=0.012), and ATD treatment (P=0.018; Student’s t-test).

aAges: ages at diagnosis.
bTBII and TSAb had disappeared. They discontinued ATD.
cThey continued to be in remission.
dThey relapsed into hyperthyroidism.
eTBII and/or TSAb persisted.
and CC genotypes and the A and C alleles of an A/C polymorphism at position 8923 in PD-L1 gene.

The study plan was reviewed and approved by the institutional review committee. Written informed consent was obtained from both the Graves’ patients and the control subjects.

Genotyping

DNA was extracted from peripheral blood using a DNA purification kit (Qiagen). The PD-L1 intron 4 position 8923 A/C polymorphism was typed using the PCR–restriction fragment length polymorphism method (PCR–RFLP). The appropriate segment of the PD-L1 gene was amplified using specific primers (5'-AATGGCTTGTTGTC-CAGAGATG-3' and 5'-GTACCACTGGAGTGCTGC-3') using premix Taq (Takara, Shiga, Japan). PCR was performed by initial denaturation for 10 min at 95°C, annealing for 30 s at 60°C, extension for 3 min at 72°C, denaturation for 30 s at 95°C (37 cycles), and a final extension for 10 min at 72°C. The amplified products (553 bp) digested with restriction enzyme Ban II (Takara) and then analyzed on 3.0% NuSieve GTG agarose (FMC BioProducts, Philadelphia, PA, USA) gels. The PCR fragments with a C allele at position 8923 were cut into three fragments (97, 130, and 326 bp), whereas the fragments with A at the same position were cut into two fragments, namely they had the restriction site only at 97 bp while also developing a 456 bp band.

Statistical analysis

Statistical analyses were done using Fisher’s exact test or Student’s t-test. A value of \( P < 0.05 \) was considered to be significantly different. Power and Hardy–Weinberg equilibrium calculations were performed using Excel (Microsoft Office Excel, 2003).

Results

Table 2 shows A/C SNP at position 8923 in the PD-L1 gene in the 327 Graves’ patients and the 192 normal control subjects (controls). Significant differences in the A/C genotype frequencies were noted between Graves’ patients and controls. The A/C and C/C genotype frequencies were higher in Graves’ patients than in controls. The A/A genotype frequencies were lower in Graves’ patients than in controls. The C-allele frequency in Graves’ patients (8.3%) was also higher than that in controls (3.1%). Significant differences in the allele frequencies (\( P = 0.0009 \)) were noted between Graves’ patients and controls, producing an odds ratio (OR) = 2.79 (95% confidence intervals (CI) = 1.47–5.28).

Table 3 shows genotype and allele frequencies of A/C SNP PD-L1 at position 8923 in the 252 Graves’ patients, who had been followed over 5–10 years. The A/C and C/C frequencies were 11.9 and 0.0% respectively in the 176 patients who continued to be in remission (group 1A), but the A/C and C/C genotype frequencies were 16.7 and 8.3% respectively in the other 24 patients who had relapsed into hyperthyroidism (group 1B). Significant differences in the genotype frequencies (\( P = 0.0102 \)) were noted between the 176 (group 1A) and the other 24 (group 1B) patients. The C-allele frequency was 6.0% in the 176 (group 1A), but it was 16.7% in the other 24 (group 1B) patients. Significant differences in the allele frequencies (\( P = 0.0143 \)) were noted between the 176 (group 1A) and the other 24 (group 1B) patients. Significant differences in the A- and C-allele frequencies were noted between groups 1A and 1B, between groups 1 and 2, and between groups 1A and 2. However, no significant differences in the A- and C-allele frequencies were noted between groups 1B and 2.

Discussion

These data demonstrate the association of a PD-L1 gene polymorphism with GD. An A/C polymorphism at position 8923 in PD-L1 gene is associated with the GD development and also with a relapse of Graves’ hyperthyroidism.

GD develops as a result of a complex interaction between genetic susceptibility genes and environmental factors (23, 24). A model analysis suggests that the GD...
patients have genetic susceptibility (25). The putative susceptibility genes for GD are immune-modifying genes (e.g., major histocompatibility complex (MHC) (24, 25), MHC class 1 chain-related gene A (MICA) (26), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) (27), CD40 (28), and butyrophilin-like protein (BTN2L1) that is likely due to a linkage disequilibrium with MHC class II (29)), thyroid-specific genes (e.g., TG (30) and PD-L1, programmed cell death-ligand 1; SNP, single nucleotide polymorphism) (31), cytokine-related genes (e.g., interleukin-1 receptor antagonist (IL-IRA) (32), IL-4 (33), and tumor necrosis factor-α (TNF-α) (34)). A recent study has shown that small effects within a disease susceptibility gene may affect the GD development with low ORs. The OR of the development of GD with PD-L1 gene is 2.94 in 173 GD patients (34). On the other hand, the allele frequencies at positions 8923 and -863A of TNF-α gene in the GD patients with evident ophthalmopathy were significantly greater than those with no or mild ophthalmopathy (ORs 2.94 and 2.30 respectively) (34). Some genes may affect the GD development with low ORs (17). The rs2076430 SNP in BTN2L1 gene and +2375 SNP in PD-1 gene were associated with the development of GD, but these genetic effects were small (ORs 1.32 and 1.14 respectively) (17, 29). Our PD-1 gene polymorphism at position 8923 contributes to the GD development with a high OR of 2.79. It is still unclear whether this PD-L1 gene polymorphism strongly contributes to the GD development, because the number of patients and controls in our study was small and the allele frequency at position 8923 in the PD-L1 gene was minor. Occasionally, several factors have been shown to induce high ORs in similar studies with disease susceptibility genes. For example, studies with a small number of patients may generate high ORs. The OR of the development of GD with MHC gene is 2.3–3.4 in 135 GD patients (44), while that with MICA gene is 2.0 in 186 GD patients (30), and that with TNF-α gene is 2.94 in 135 GD patients (44). On the other hand, the OR of the development of GD with CTLA-4 gene is 1.49

Table 3 Genotype and allele frequencies of A/C SNP PD-L1 gene at position 8923 in the 252 Graves’ patients.

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Group 1 (200)</th>
<th>Group 2 (52)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Remission</td>
<td>B. Relapsed</td>
</tr>
<tr>
<td></td>
<td>(176) n (%)</td>
<td>(24) n (%)</td>
</tr>
<tr>
<td>A/A</td>
<td>155 (88.1)</td>
<td>18 (75.0)</td>
</tr>
<tr>
<td>A/C</td>
<td>21 (11.9)</td>
<td>4 (16.7)</td>
</tr>
<tr>
<td>C/C</td>
<td>0 (0.0)</td>
<td>2 (8.3)</td>
</tr>
</tbody>
</table>

Allele

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype</td>
<td>331 (94.0)</td>
<td>40 (83.3)</td>
</tr>
<tr>
<td></td>
<td>21 (6.0)</td>
<td>8 (16.7)</td>
</tr>
</tbody>
</table>

PD-L1, programmed cell death-ligand 1; SNP, single nucleotide polymorphism; ATD, antithyroid drugs. Significant differences in A- and C-allele frequencies were noted between groups 1A and 1B (P=0.0143), between groups 1 and 2 (P=0.0187), and between groups 1A and 2 (P=0.0037; Fisher’s exact test). However, no significant differences in A, the C-allele frequencies were observed between groups 1B and 2 (P=0.8194; Fisher’s exact test).
in 22,038 GD patients (46), that with BTNL-2 gene is 1.32 in 16,586 GD patients (29), and that with PD-1 gene is 1.14 in 4130 GD patients (17). We performed the power calculations with the distribution of the PD-L1 gene polymorphism in the 327 GD patients and the 192 controls. The power was therefore 24% to detect an OR = 1.5 and P = 0.05. Our PD-L1 gene polymorphism at 8923 contributes to the GD development with an OR of 2.79. This OR of 2.79 seems to be high. The minor frequency of the C allele may generate this high OR. The C-allele frequency in the Graves’ patients (8.3%) was higher than that in the controls (3.1%), the difference being 5.2%. This could thus have produced the erroneously high OR of 2.79. There are some limitations in our study.

We describe that A/C SNP at 8923 might be one of the candidate gene polymorphisms for GD. Further studies will be required to determine a clear association of the PD-L1 gene polymorphism with the GD development in large numbers of patients, as well as patients with other different genetic backgrounds.

**Disclosure**

We have no conflict of interest that would prejudice its impartiality.

**References**


